Showing results (11-20 of 473) with videos related to
Sort By:
Pageof 48
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?Federico Caligaris-Cappio, Paolo GhiaBlood|March 17, 2012
Monoclonal B-cell lymphocytosis: right track or red herring?Paolo Ghia, Federico Caligaris-CappioBest Practice & Research. Clinical Haematology|August 21, 2007
The normal counterpart to the chronic lymphocytic leukemia B cellFederico Caligaris-Cappio, Paolo GhiaMediterranean Journal of Hematology and Infectious Diseases|March 13, 2019
Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?Antonio Cuneo, Robin FoàUrologia|January 15, 2014
[Use of 5-phosphodiesterase inhibitors in patients with LUTS secondary to BPH: our experience and review of the literature]Lucio Dell'Atti, Antonio CuneoHemasphere|October 9, 2024
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide studyGian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, et al.Hematology/Oncology Clinics of North America|April 9, 2013
MBL versus CLL: how important is the distinction?Lydia Scarfò, Claudia Fazi, Paolo GhiaCurrent Opinion in Oncology|October 9, 2019
The evolving treatment landscape of chronic lymphocytic leukemiaLuana Schiattone, Paolo Ghia, Lydia ScarfòCancer Journal (Sudbury, Mass.)|November 26, 2019
Relevance of Minimal Residual Disease in the Era of Targeted AgentsSilvia Heltai, Paolo Ghia, Lydia ScarfòSeminars in Cancer Biology|December 25, 2013
The microenvironment in lymphomas--dissecting the complex crosstalk between tumor cells and 'by-stander' cellsRichard Rosenquist, Frédéric Davi, Paolo GhiaPageof 48